A股異動丨熱景生物(688068.SH)一字漲停 預計一季度淨利同比暴增超1000倍
格隆匯4月13日丨熱景生物(688068.SH)一字漲停,報69.64元,股價創去年8月以來新高,年內累計漲幅達62%,總市值43億元。熱景生物昨日盤後公吿稱,預計第一季度淨利潤為5.6億-6.6億元,同比增長109125.67%-128630.25%。2021年一季度,公司的新型冠狀病毒2019n-CoV抗原檢測試劑盒(前鼻腔)和新型冠狀病毒2019n-CoV抗原檢測試劑盒(唾液)兩款新型冠狀病毒抗原快速檢測試劑產品分別於3月2日和22日,獲得德國聯邦藥品和醫療器械研究所(BfArM)用於居家自由檢測的認證,可以在德國的商超、藥店、互聯網商店等銷售,導致公司的外貿訂單爆發式增長。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.